VEGF-A165B is cytoprotective and antiangiogenic in the retina

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 8, 2010, Pages 4273-4281

  Magnussen, Anette L ^a   Rennel, Emma S ^a   Hua, Jing ^a   Bevan, Heather S ^a   Long, Nicholas Beazley ^a   Lehrling, Christina ^b   Gammons, Melissa ^a   Floege, Juergen ^c   Harper, Steven J ^a   Agostini, Hansjürgen T ^b   Bates, David O ^a   Churchill, Amanda J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RECOMBINANT VASCULOTROPIN; RECOMBINANT VASCULOTROPIN A165B; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; APTAMER; IGFBP3 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SOMATOMEDIN BINDING PROTEIN; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROTECTION; CELL SURVIVAL; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; ENDOTHELIUM CELL; IC 50; MONOLAYER CULTURE; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETINA NEOVASCULARIZATION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; DRUG INTERACTION; EPITHELIUM CELL; HALF LIFE TIME; HUMAN; METABOLISM; NEWBORN; RAT; RETINA BLOOD VESSEL; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, NEWBORN; APTAMERS, NUCLEOTIDE; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; EPITHELIAL CELLS; HALF-LIFE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MICE; MICE, INBRED C57BL; RATS; RECOMBINANT PROTEINS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77955866848     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4296     Document Type: Article

References (54)

1. Roth F, Bindewald A, Holz FG. Key pathophysiologic pathways in age-related macular disease. Graefes Arch Clin Exp Ophthalmol. 2004;242:710-716.
2. Kinose F, Roscilli G, Lamartina S, et al. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol Vis. 2005;11:366-373.
3. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
4. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995;1:182-193.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
6. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.
7. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ. 2006;290:H547-H559.
8. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-4131.
9. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, et al. Recombinant human VEGF165b protein is an effective anti- cancer agent in mice. Eur J Cancer. 2008;44:1883-1894.
10. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822-7835.
11. Qiu Y, Bevan H, Weeraperuma S, et al. Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB J. 2008;22:1104-1112.
12. Cebe Suarez S, Pieren M, Cariolato L, et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci. 2006;63: 2067-2077.
13. Rennel E, Waine E, Guan H, et al. The endogenous antiangiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008;98:1250-1257.
14. Varey AH, Rennel ES, Qiu Y, et al. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008;98:1366-1379.
15. Rennel ES, Varey AH, Churchill AJ, et al. VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularization and tumor growth in vivo. Br J Cancer. 2009;101(7): 1183-1193.
16. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422-2427.
17. Ergorul C, Ray A, Huang W, Darland D, Luo ZK, Grosskreutz CL. Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma. Mol Vis. 2008;14:1517-1524.
18. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
19. Bevan HS, van den Akker NM, Qiu Y, et al. The alternatively spliced antiangiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol. 2008;110:57-67.
20. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
21. Chan-Ling T. Glial, vascular, and neuronal cytogenesis in wholemounted cat retina. Microsc Res Tech. 1997;36:1-16.
22. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003; 161:1163-1177.
23. Jauregui HO, Hayner NT, Driscoll JL, Williams-Holland R, Lipsky MH, Galletti PM. Trypan blue dye uptake and lactate dehydrogenase in adult rat hepatocytes-freshly isolated cells, cell suspensions, and primary monolayer cultures. In Vitro. 1981;17:1100-1110.
24. Krohne TU, Hunt S, Holz FG. Effect of 308 nm excimer laser irradiation on retinal pigment epithelium cell viability in vitro. Br J Ophthalmol. 2009;93:91-95.
25. Hamdollah Zadeh MA, Glass CA, Magnussen A, Hancox JC, Bates DO. VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 2008;15:605-614.
26. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest. 1999;104:913-923.
27. Whittles CE, Pocock TM, Wedge SR, et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation. 2002;9:513-522.
28. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res. 2008;68:4683-4692.
29. Ong JM, Aoki AM, Seigel GM, et al. Oxysterol-induced toxicity in R28 and ARPE-19 cells. Neurochem Res. 2003;28:883-891.
30. Nowak DG, Amin EM, Rennel ES, et al. Regulation of VEGF splicing from pro-angiogenic to antiangiogenic isoforms-a novel therapeutic strategy for angiogenesis. J Biol Chem. 2010;285(8):5532-5540.
31. Nowak DG, Woolard J, Amin EM, et al. Expression of pro- and antiangiogenic isoforms of VEGF is differentially regulated by known splicing and growth factors. J Cell Sci. 2008;121:3487-3495.
32. Slomiany MG, Rosenzweig SA. Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol Cell Physiol. 2004;287:C746-C753.
33. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis. 2006;12:626-632.
34. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-1321.
35. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130:691-703.
36. Hua J, Spee C, Kase S, et al. Recombinant human VEGF165b inhibits experimental choroidal neovascularisation. Invest Ophthalmol Vis Sci. 2010;51;4282-4288.
37. Anderson HR, Stitt AW, Gardiner TA, Archer DB. Diabetic retinopathy: morphometric analysis of basement membrane thickening of capillaries in different retinal layers within arterial and venous environments. Br J Ophthalmol. 1995;79:1120-1123.
38. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152.
39. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
40. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.
41. Stitt AW, Gardiner TA, Archer DB. Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol. 1995;79:362-367.
42. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 1996;97:2883-2890.
43. Sun HW, Li CJ, Chen HQ, et al. Involvement of integrins, MAPK, and NF-k{cyrillic}B in regulation of the shear stress-induced MMP-9 expression in endothelial cells. Biochem Biophys Res Commun. 2007; 353:152-158.
44. Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009;136:839-851.
45. Benest AV, Augustin HG. Cancer: blood vessels kept quiet. Nature. 2009;458:41-42.
46. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One. 2008;3:e3554.
47. Bogaert E, Van Damme P, Van Den Bosch L, Robberecht W. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve. 2006;34:391-405.
48. Tolosa L, Mir M, Asensio VJ, Olmos G, Llado J. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem. 2008;105:1080-1090.
49. Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol. 2004;137:504-510.
50. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
51. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
52. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia- response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001;28: 131-138.
53. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136.
54. Peters S, Heiduschka P, Julien S, et al. Ultra structural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007;143:995-1002.